Prospective study of ERCC1,BRCA1,and RRM1 expression on the individualized treatment of advanced non-small cell lung cancer
DING Jian-wu1，2 TANG Luo-yong1，2 AI Su-fen1，2 ZHANG Feng-hao1，2 HUANG Long1，2 HU Rong-huan1，2 XIONG Qiang1，2
1.Key Laboratory of Jiangxi Provincial Tumor Foundation and Transformation Research,Nanchang 330000,China;
2.Department of Oncology,the Second Affiliated Hospital of Nanchang University in Jiangxi Province,Nanchang 330000,China
Abstract：ObjectiveTo investigate the application value of excision repair cross-complementing gene 1(ERCC1),breast cancer susceptibility gene 1 (BRCA1),and ribonucleotide reductase M1 subunit(RRM1)expression in the individualized treatment of advanced non-small cell lung cancer(NSCLC).MethodsFrom June 2015 to August 2016,50 patients with advanced NSCLC visited our hospital were recruited as research subjects.Using an odd/even number grouping model,they were grouped and there were 25 cases in each group.In the experimental group,the level of ERCC1,BRCA1,and RRM1 were tested,and the corresponding chemotherapy regimen was selected based on the outcomes.In the conventional group,Gemcitabine combined with Cisplatin was provided.The therapeutic effect was compared between the two groups.ResultsThe total effective rate of chemotherapy in the experimental group was 72.00%,which was obviously higher than that of the conventional group,and there was a statistical difference(P＜0.05).The quality of life in both groups was improved compared with that before chemotherapy,but there was no significant difference of PS score between the two groups(P＞0.05).In the experimental group,there were blood system reaction in 12 cases,digestive tract reaction in 7 cases,and other in 3 ones.In the conventional group,there were blood system reaction in 13 cases,digestive tract reaction in 7 cases,and other in 3 ones.There was no statistical difference of the incidence of adverse reaction between the two groups(P＞0.05).ConclusionTest for the level of ERCC1,BRCA1,and RRM1 and guidance of clinical treatment in NSCLC patients based on the outcomes are beneficial to improve the clinical therapeutic effect.
京公网安备 11010502046607号